Want to see IN:VIVIMEDLAB full AI Analyst Report?
Vivimed Labs Limited (VIVIMEDLAB) Stock Statistics & Valuation Metrics
Total Valuation
Vivimed Labs Limited has a market cap or net worth of INR 506.60M. The enterprise value is INR 4.24B.
- Market Cap
- INR 506.60M
- Enterprise Value
- INR 4.24B
Share Statistics
Vivimed Labs Limited has 82,913,910 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 82,913,910
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Vivimed Labs Limited’s return on equity (ROE) is 0.84 and return on invested capital (ROIC) is -28.28%.
- Return on Equity (ROE)
- 0.84
- Return on Assets (ROA)
- -0.23
- Return on Invested Capital (ROIC)
- -28.28%
- Return on Capital Employed (ROCE)
- -0.58
- Revenue Per Employee
- 1.19M
- Profits Per Employee
- -3.01M
- Employee Count
- 586
- Asset Turnover
- 0.09
- Inventory Turnover
- 9.81
Valuation Ratios
The current PE Ratio of Vivimed Labs Limited is -0.26. Vivimed Labs Limited’s PEG ratio is 0.00.
- PE Ratio
- -0.26
- PS Ratio
- 0.66
- PB Ratio
- -0.22
- Price to FCF
- 6.79
- Price to Operating Cash Flow
- 5.95
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Vivimed Labs Limited had revenue of 699.89M and earned -1.76B in profits. Earnings per share was -21.15.
- Revenue
- 699.89M
- Gross Profit
- -547.76M
- Operating Income
- -1.78B
- Pretax Income
- -1.76B
- Net Income
- -1.76B
- EBITDA
- -1.46B
- Earnings Per Share (EPS)
- -21.15
Cash Flow
In the last 12 months, operating cash flow was 77.03M and capital expenditures -9.47M, giving a free cash flow of 67.56M billion.
- Operating Cash Flow
- 77.03M
- Free Cash Flow
- 67.56M
- Free Cash Flow per Share
- 0.81
Dividends & Yields
Vivimed Labs Limited pays an annual dividend of INR 0.40, resulting in a dividend yield of ―
- Dividend Per Share
- INR 0.40
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 14.73%
- Earnings Yield
- -384.79%
Stock Price Statistics
- Beta
- 0.43
- 52-Week Price Change
- 24.69%
- 50-Day Moving Average
- 6.23
- 200-Day Moving Average
- 6.36
- Relative Strength Index (RSI)
- 46.87
- Average Volume (3m)
- 16.57K
Important Dates
Vivimed Labs Limited upcoming earnings date is Nov 12, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Jul 17, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- Sep 19, 2018
Financial Position
Vivimed Labs Limited as a current ratio of 0.37, with Debt / Equity ratio of -188.70%
- Current Ratio
- 0.37
- Quick Ratio
- 0.35
- Debt to Market Cap
- 8.63
- Net Debt to EBITDA
- -2.71
- Interest Coverage Ratio
- -42.80
Taxes
In the past 12 months, Vivimed Labs Limited has paid 1.38M in taxes.
- Income Tax
- 1.38M
- Effective Tax Rate
- -0.00
Enterprise Valuation
Vivimed Labs Limited EV to EBITDA ratio is -3.02, with an EV/FCF ratio of 65.39.
- EV to Sales
- 6.31
- EV to EBITDA
- -3.02
- EV to Free Cash Flow
- 65.39
- EV to Operating Cash Flow
- 57.36
Balance Sheet
Vivimed Labs Limited has INR 13.56M in cash and marketable securities with INR 3.97B in debt, giving a net cash position of -INR 3.96B billion.
- Cash & Marketable Securities
- INR 13.56M
- Total Debt
- INR 3.97B
- Net Cash
- -INR 3.96B
- Net Cash Per Share
- -INR 47.76
- Tangible Book Value Per Share
- -INR 43.31
Margins
Gross margin is -47.95%, with operating margin of -255.03%, and net profit margin of -252.14%.
- Gross Margin
- -47.95%
- Operating Margin
- -255.03%
- Pretax Margin
- -251.95%
- Net Profit Margin
- -252.14%
- EBITDA Margin
- -208.75%
- EBIT Margin
- -245.97%
Analyst Forecast
The average price target for Vivimed Labs Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -39.80%
- EPS Growth Forecast
- -452.04%
Scores
- Smart Score
- ―
- AI Score
- 45